KRAS and breast carcinoma: Four specific genetic mutations, human epidermal growth factor receptor 2 (HER2) for breast cancer, BReast CAncer genes 1 and 2 (BRCA1 and BRCA2) for ovarian cancer, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) wild-type for colorectal cancer, and programed death ligand 1 (PD-L1) expression for NSCLC were explored for therapeutic class labeling potential.